NCCN Guidelines Updates: Pancreatic Cancer
NCCN Guidelines Updates: Pancreatic Cancer
复制标题
DOI：
10.6004/jnccn.2019.5007
复制
发表时间：
2019-05-01
影响因子：
13.4
通讯作者：
Tempero, Margaret A.
中科院分区：
文献类型：
--
作者：
Tempero, Margaret A.
随着生殖细胞和体细胞分子谱的完善，以及辅助化疗的有益效果，胰腺癌的结局变得不那么令人沮丧。NCCN胰腺癌指南反映了这些进展，并建议临床医生考虑对所有胰腺癌患者进行生殖细胞检测，并考虑对转移性疾病患者进行分子分析。指南进一步建议临床医生考虑对能够耐受的患者使用改良FOLFIRINOX（亚叶酸/5-FU/伊立替康/奥沙利铂）进行辅助治疗。
Outcomes for pancreatic cancer are becoming less discouraging with the refinement of molecular profiling, both germline and somatic, and beneficial effects seen with adjuvant chemotherapy. The NCCN Guidelines for Pancreatic Adenocarcinoma reflect these advances, and recommend that clinicians consider germline testing for all patients with pancreatic cancer and consider a molecular analysis for those with metastatic disease. The guidelines further recommend that clinicians consider adjuvant therapy with modified FOLFIRINOX (leucovorin/5-FU/irinotecan/oxaliplatin) for patients who are able to tolerate it.